Industry Verticals »

All Categories

Insights »

About TMR »

Brucellosis Vaccine Market Outlook, 2021-2031

Brucellosis Vaccine Market (Type: RB51 Vaccine, S19 Vaccine, and Others; Vaccine Type: DNA Vaccine, Subunit Vaccine, Vector Vaccine, and Recombinant Vaccine; Application: Cattle, Sheep & Goat, and Others; and Distribution Channel: Veterinary Hospitals & Clinics, Retail Channels, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Healthcare Providers Acquire Financial Aid amid Ongoing COVID-19 Outbreak

Out-of-hospital care is anticipated to surge during the COVID-19 period. Stakeholders in the brucellosis vaccine market are increasing the availability of home healthcare providers, rehabilitation facilities, and long term care facilities. In-patient and community-based providers should review the current capacity for patients in both settings and plan for future pandemic-like situations.

Companies in the brucellosis vaccine market are scrambling to maintain robust supply chains to improve patient outcomes and meet demands. They are looking for financial aid by governments and organizing employee wellness programs to prevent & mitigate burnout, review pay & benefits compared with the industry average. Interrupted clinical research and clinical trial activities are now being conducted utilizing telehealth options wherever possible.

To know the scope of our report Get a Sample on Brucellosis Vaccine Market

Educational & Training Programs Help Control Brucellosis Disease in Colombia

Due to the presence of brucellosis in several susceptible production livestock systems scattered throughout Colombia, companies in the brucellosis vaccine market are making plans for its control, prevention, and eradication over the years. However, despite extensive efforts, brucellosis prevalence has fluctuated over the years without any trend of decreasing. Hence, companies are creating awareness about high impact educational and training programs required to address the disease in a comprehensive manner.

Companies in the Colombia brucellosis vaccine market are targeting vulnerable groups such as traditional smallholders, veterinary authorities, and communities in low productivity regions for their educational and training programs.

Get a glimpse of the in-depth analysis through our Report Brochure

India Holds Lucrative Incremental Opportunities for Brucellosis Vaccine Manufacturers

The global brucellosis vaccine market is projected to grow at a CAGR of 4% during the forecast period. Companies are tapping value-grab opportunities in India, since the Animal Husbandry Department in Yadgir has planned to vaccinate cattle and buffalo calves to prevent brucellosis disease under the National Animal Disease Control Programme (NADCP). Several thousand cattle and buffalo calves are being vaccinated under this flagship scheme launched by the Union Government of India.

Since brucellosis is a serious infectious disease that can cause abortion or loss of reproductivity, companies in the India brucellosis vaccine market are increasing output capacities to improve clinical outcomes in cattle and buffalo. Mass inoculation of cattle and buffalo is being conducted on priority in India to prevent the spread of the disease from animals to human beings.

Guinea Pig Model Holds Promising Potentials to Develop Well-tolerated Brucellosis Vaccines

Apart from developing vaccines for animals, companies in the brucellosis vaccine market are diversifying their research capabilities to innovate in vaccines for humans.

In order to develop new vaccine candidates, there is a need to comply with the set industry standards before selecting the viral vectors and the method for preparing & using the vaccine. Companies are increasing their R&D capabilities using the study of protection of the vaccine with the help of guinea pigs, including various options for administering, dose, and frequency. They are innovating in brucellosis vaccines that can be well-tolerated in humans by upgrading the production technology and testing in healthcare practice.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Stakeholders in the brucellosis vaccine market are reviewing financial assistance programs associated with COVID-19 appropriations for eligibility. Restricted budgets for brucellosis control in Colombia is affecting the overall animal welfare in the region. Hence, stakeholders in Colombia should increase efforts for important financial investments based on sustained cooperation between governmental institutions, industry, and farmers for developing affordable and effective strategies to control the disease. On-farm detection involves the use of a screening test, followed by a confirmatory test. Testing is mandatory for international trade, animal movements in Colombia, and for clinically suspected animals. This involves the Rose Bengal Plate Test (RBPT) or Indirect ELISA as a screening test.

Brucellosis Vaccine Market: Overview

  • Brucellosis, often referred as Bang's disease, contagious abortion, or infectious abortion, affects cattle, buffaloes, sheep, goats, camels, pigs, dogs, horses, deer, yaks, and feral animals as well as humans. The disease causes considerable economic loss and is a serious public health concern.
  • Various types of brucellosis species are found in different kinds of animals including Brucella abortus (from cattle), Brucella abortus (from cattle), Brucella abortus (from cattle), Brucella abortus (from cattle), and others
  • Rise in prevalence of brucellosis and increase in awareness among people are projected to drive the global brucellosis vaccine market during the forecast period

Brucellosis Vaccine Market: Key Drivers

  • Most human zoonotic infections are transmitted by livestock. Zoonotic diseases account for 61% of the total animal diseases. For instance, brucellosis and foot-and-mouth are the major diseases in animals. Increase in number of cases of brucellosis propels the global brucellosis vaccine market. Rise in the number of brucellosis cases in India, Brazil, Mexico, and other countries is likely to drive the global market. The global burden of human brucellosis is quite high. Over 500,000 infections are caused by animals across the world every year.
  • Awareness about animal diseases, their symptoms, and medications is most important for livestock owners. Several animal health awareness programs have been conducted to increase awareness among people. In India, the National Animal Disease Control Programme (NADCP) is a flagship scheme launched by Honorable Prime Minister in September 2019 for control of foot & mouth disease and brucellosis by vaccinating 100% cattle, buffalo, sheep, goat, and pig population against FMD and 100% bovine female calves of four to eight months of age against brucellosis.

Brucellosis Vaccine Market: Segmentation

  • In terms of type, the global brucellosis vaccine market has been classified into RB51 vaccine, S19 vaccine, and others
  • Based on vaccine type, the global brucellosis vaccine market has been categorized into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine
  • In terms of application, the global brucellosis vaccine market has been segregated into cattle, sheep & goat, and others
  • Based on distribution channel, the global brucellosis vaccine market has been divided into veterinary hospitals & clinics, retail channels, and others
  • Each of the segments has been analyzed in detail for brucellosis vaccine trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The brucellosis vaccine market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Brucellosis Vaccine Market: Regional Overview

  • In terms of region, the global brucellosis vaccine market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • Asia Pacific accounted for the largest share of the global brucellosis vaccine market in 2020 and the trend is projected to continue during the forecast period. Growth of the brucellosis vaccine market in the region can be ascribed to presence of major players and high cattle population.
  • Asia Pacific is anticipated to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are expected to propel the brucellosis vaccine market in the region.
  • The current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2017 to 2031 along with CAGRs for the period from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process

Major Players

  • The report concludes with the company profiles section, which includes key information about the major players in the global brucellosis vaccine market
  • Leading players analyzed in the report are
    • Merck Animal Health
    • Ceva Sante Animale
    • CZ Vaccines
    • Colorado Serum Company
    • Indian Immunologicals Ltd.
    • Hester Biosciences Limited
    • Veterinary Technologies Corporation
    • Fivet Animal Health
    • Jordan Bio-industries Center
    • Laboratories Tornel
  • Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Brucellosis Vaccine Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 253.1 Mn

Market Forecast Value in 2031

US$ 387.4 Mn

Growth Rate (CAGR)

4%

Forecast Period

2021–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape
  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation
  • By Type
    • RB51 Vaccine
    • S19 Vaccine
    • Others
  • By Vaccine Type
    • DNA Vaccine
    • Subunit Vaccine
    • Vector Vaccine
    • Recombinant Vaccine
  • By Application
    • Cattle
    • Sheep & Goat
    • Others
  • By Distribution Channel
    • Veterinary Hospitals & Clinics
    • Retail Channels
    • Others

Regions Covered
  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled
  • Merck Animal Health
  • CEVA SANTE ANIMALE
  • CZ Vaccines
  • Colorado Serum Company
  • Indian Immunologicals Ltd.
  • Hester Biosciences Limited
  • Veterinary Technologies Corporation
  • Fivet Animal Health
  • Jordan Bio-industries Center
  • Laboratories Tornel

Customization Scope

Available upon request

Pricing

Available upon request

Brucellosis Vaccine Market – Segmentation

TMR’s study on the global brucellosis vaccine market includes information divided into five segments: type, vaccine type, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global brucellosis vaccine market are discussed in detail.

Type
  • RB51 Vaccine
  • S19 Vaccine
  • Others
Vaccine Type
  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine
Application
  • Cattle
  • Sheep & Goat
  • Others
Distribution Channel
  • Veterinary Hospitals & Clinics
  • Retail Channels
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of brucellosis vaccine market?

Brucellosis vaccine market to reach valuation of US$ 387.4 Mn by 2031

What is the anticipated CAGR of the brucellosis vaccine market in the forecast period?

Brucellosis vaccine market is projected to grow at a CAGR of 4% during 2021-2031

What are the key driving factors for the growth of the brucellosis vaccine market?

Brucellosis vaccine market is driven by increase in the number of animals suffering from brucellosis

Which is the rising prominent segment in the brucellosis vaccine market?

The RB51 vaccine segment dominated the global brucellosis vaccine market in 2020, and the trend is expected to continue during the forecast period.

Who are the key players in the global brucellosis vaccine market?

Key players operating in the global brucellosis vaccine market include Merck Animal Health, Ceva Sante Animale, CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd.

    1. Preface

        1.1. Report Scope and Market Segmentation

        1.2. Research Highlights

    2. Assumptions and Research Methodology

        2.1. Assumptions and Acronyms Used

        2.2. Research Methodology

    3. Executive Summary

    4. Market Overview

        4.1. Introduction

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunity

        4.3. Global Brucellosis Vaccine Market Forecast

        4.4. Global Brucellosis Vaccine Market Outlook

    5. Market Outlook

        5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

        5.2. Disease Prevalence globally with key countries

        5.3. Regulatory Scenario

        5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Global Brucellosis Vaccine Market Analysis and Forecast, by Type

        6.1. Introduction

        6.2. Global Brucellosis Vaccine Market Value Share Analysis, by Type

        6.3. Global Brucellosis Vaccine Market Forecast, by Type

            6.3.1. RB51 Vaccine

            6.3.2. S19 Vaccine

            6.3.3. Others

        6.4. Global Brucellosis Vaccine Market Analysis, by Type

        6.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Type

    7. Global Brucellosis Vaccine Market Analysis and Forecast, by Vaccine Type

        7.1. Introduction

        7.2. Global Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type

        7.3. Global Brucellosis Vaccine Market Forecast, by Vaccine Type

            7.3.1. DNA Vaccine

            7.3.2. Subunit Vaccine

            7.3.3. Vector Vaccine

        7.4. Recombinant Vaccine

        7.5. Global Brucellosis Vaccine Market Analysis, by Vaccine Type

        7.6. Global Brucellosis Vaccine Market Attractiveness Analysis, by Vaccine Type

    8. Global Brucellosis Vaccine Market Analysis and Forecast, by Application

        8.1. Introduction

        8.2. Global Brucellosis Vaccine Market Value Share Analysis, by Application

        8.3. Global Brucellosis Vaccine Market Forecast, by Application

            8.3.1. Cattle

            8.3.2. Sheep & Goat

            8.3.3. Others

        8.4. Global Brucellosis Vaccine Market Analysis, by Application

        8.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Application

    9. Global Brucellosis Vaccine Market Analysis and Forecast, by Distribution Channel

        9.1. Introduction

        9.2. Global Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel

        9.3. Global Brucellosis Vaccine Market Forecast, by Distribution Channel

            9.3.1. Veterinary Hospitals & Clinics

            9.3.2. Retail Channels

            9.3.3. Others

        9.4. Global Brucellosis Vaccine Market Analysis, by Distribution Channel

        9.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Distribution Channel

    10. Global Brucellosis Vaccine Market Analysis, by Region

        10.1. Global Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Region

        10.2. Global Brucellosis Vaccine Market Forecast, by Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

    11. North America Brucellosis Vaccine Market Analysis

        11.1. North America Brucellosis Vaccine Market Overview

        11.2. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country

        11.3. North America Brucellosis Vaccine Market Forecast, by Country

            11.3.1. U.S.

            11.3.2. Canada

        11.4. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

        11.5. North America Brucellosis Vaccine Market Forecast, by Type

            11.5.1. RB51 Vaccine

            11.5.2. S19 Vaccine

            11.5.3. Others

        11.6. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

        11.7. North America Brucellosis Vaccine Market Forecast, by Vaccine Type

            11.7.1. DNA Vaccine

            11.7.2. Subunit Vaccine

            11.7.3. Vector Vaccine

            11.7.4. Recombinant Vaccine

        11.8. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

        11.9. North America Brucellosis Vaccine Market Forecast, by Application

            11.9.1. Cattle

            11.9.2. Sheep & Goat

            11.9.3. Others

        11.10. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

        11.11. North America Brucellosis Vaccine Market Forecast, by Distribution Channel

            11.11.1. Veterinary Hospitals & Clinics

            11.11.2. Retail Channels

            11.11.3. Others

    12. Europe Brucellosis Vaccine Market Analysis

        12.1. Europe Brucellosis Vaccine Market Overview

        12.2. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

        12.3. Europe Brucellosis Vaccine Market Forecast, by Country/Sub-region

            12.3.1. Germany

            12.3.2. U.K.

            12.3.3. France

            12.3.4. Spain

            12.3.5. Italy

            12.3.6. Rest of Europe

        12.4. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

        12.5. Europe Brucellosis Vaccine Market Forecast, by Type

            12.5.1. RB51 Vaccine

            12.5.2. S19 Vaccine

            12.5.3. Others

        12.6. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

        12.7. Europe Brucellosis Vaccine Market Forecast, by Vaccine Type

            12.7.1. DNA Vaccine

            12.7.2. Subunit Vaccine

            12.7.3. Vector Vaccine

            12.7.4. Recombinant Vaccine

        12.8. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

        12.9. Europe Brucellosis Vaccine Market Forecast, by Application

            12.9.1. Cattle

            12.9.2. Sheep & Goat

            12.9.3. Others

        12.10. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

        12.11. Europe Brucellosis Vaccine Market Forecast, by Distribution Channel

            12.11.1. Veterinary Hospitals & Clinics

            12.11.2. Retail Channels

            12.11.3. Others

    13. Asia Pacific Brucellosis Vaccine Market Analysis

        13.1. Asia Pacific Brucellosis Vaccine Market Overview

        13.2. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

        13.3. Asia Pacific Brucellosis Vaccine Market Forecast, by Country/Sub-region

            13.3.1. China

            13.3.2. Japan

            13.3.3. India

            13.3.4. Australia & New Zealand

            13.3.5. Rest of Asia Pacific

        13.4. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

        13.5. Asia Pacific Brucellosis Vaccine Market Forecast, by Type

            13.5.1. RB51 Vaccine

            13.5.2. S19 Vaccine

            13.5.3. Others

        13.6. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

        13.7. Asia Pacific Brucellosis Vaccine Market Forecast, by Vaccine Type

            13.7.1. DNA Vaccine

            13.7.2. Subunit Vaccine

            13.7.3. Vector Vaccine

            13.7.4. Recombinant Vaccine

        13.8. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

        13.9. Asia Pacific Brucellosis Vaccine Market Forecast, by Application

            13.9.1. Cattle

            13.9.2. Sheep & Goat

            13.9.3. Others

        13.10. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

        13.11. Asia Pacific Brucellosis Vaccine Market Forecast, by Distribution Channel

            13.11.1. Veterinary Hospitals & Clinics

            13.11.2. Retail Channels

            13.11.3. Others

    14. Latin America Brucellosis Vaccine Market Analysis

        14.1. Latin America Brucellosis Vaccine Market Overview

        14.2. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

        14.3. Latin America Brucellosis Vaccine Market Forecast, by Country/Sub-region

            14.3.1. Brazil

            14.3.2. Mexico

            14.3.3. Rest of Latin America

        14.4. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

        14.5. Latin America Brucellosis Vaccine Market Forecast, by Type

            14.5.1. RB51 Vaccine

            14.5.2. S19 Vaccine

            14.5.3. Others

        14.6. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

        14.7. Latin America Brucellosis Vaccine Market Forecast, by Vaccine Type

            14.7.1. DNA Vaccine

            14.7.2. Subunit Vaccine

            14.7.3. Vector Vaccine

            14.7.4. Recombinant Vaccine

        14.8. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

        14.9. Latin America Brucellosis Vaccine Market Forecast, by Application

            14.9.1. Cattle

            14.9.2. Sheep & Goat

            14.9.3. Others

        14.10. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

        14.11. Latin America Brucellosis Vaccine Market Forecast, by Distribution Channel

            14.11.1. Veterinary Hospitals & Clinics

            14.11.2. Retail Channels

            14.11.3. Others

    15. Middle East & Africa Brucellosis Vaccine Market Analysis

        15.1. Middle East & Africa Brucellosis Vaccine Market Overview

        15.2. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region

        15.3. Middle East & Africa Brucellosis Vaccine Market Forecast, by Country/Sub-region

            15.3.1. GCC Countries

            15.3.2. South Africa

            15.3.3. Rest of Middle East & Africa

        15.4. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type

        15.5. Middle East & Africa Brucellosis Vaccine Market Forecast, by Type

            15.5.1. RB51 Vaccine

            15.5.2. S19 Vaccine

            15.5.3. Others

        15.6. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type

        15.7. Middle East & Africa Brucellosis Vaccine Market Forecast, by Vaccine Type

            15.7.1. DNA Vaccine

            15.7.2. Subunit Vaccine

            15.7.3. Vector Vaccine

            15.7.4. Recombinant Vaccine

        15.8. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application

        15.9. Middle East & Africa Brucellosis Vaccine Market Forecast, by Application

            15.9.1. Cattle

            15.9.2. Sheep & Goat

            15.9.3. Others

        15.10. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel

        15.11. Middle East & Africa Brucellosis Vaccine Market Forecast, by Distribution Channel

            15.11.1. Veterinary Hospitals & Clinics

            15.11.2. Retail Channels

            15.11.3. Others

    16. Competition Landscape

        16.1. Company Profiles

            16.1.1. Merck Animal Health

                16.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.1.2. Product Portfolio

                16.1.1.3. Financial Overview

                16.1.1.4. SWOT Analysis

                16.1.1.5. Strategic Overview

            16.1.2. Ceva Sante Animale

                16.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.2.2. Product Portfolio

                16.1.2.3. SWOT Analysis

                16.1.2.4. Strategic Overview

            16.1.3. CZ Vaccines

                16.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.3.2. Product Portfolio

                16.1.3.3. SWOT Analysis

                16.1.3.4. Strategic Overview

            16.1.4. Colorado Serum Company

                16.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.4.2. Product Portfolio

                16.1.4.3. SWOT Analysis

                16.1.4.4. Strategic Overview

            16.1.5. Indian Immunologicals Ltd.

                16.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.5.2. Product Portfolio

                16.1.5.3. SWOT Analysis

                16.1.5.4. Strategic Overview

            16.1.6. Hester Biosciences Limited

                16.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.6.2. Product Portfolio

                16.1.6.3. Financial Overview

                16.1.6.4. SWOT Analysis

                16.1.6.5. Strategic Overview

            16.1.7. Veterinary Technologies Corporation.

                16.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.7.2. Product Portfolio

                16.1.7.3. SWOT Analysis

                16.1.7.4. Strategic Overview

            16.1.8. Fivet Animal Health

                16.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.8.2. Product Portfolio

                16.1.8.3. SWOT Analysis

                16.1.8.4. Strategic Overview

            16.1.9. Jordan Bio-industries Center

                16.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.9.2. Product Portfolio

                16.1.9.3. SWOT Analysis

                16.1.9.4. Strategic Overview

            16.1.10. Laboratories Tornel

                16.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.1.10.2. Product Portfolio

                16.1.10.3. SWOT Analysis

                16.1.10.4. Strategic Overview

    List of Tables

    Table 01: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2018–2030

    Table 02: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

    Table 03: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

    Table 04: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 05: Global Brucellosis Vaccine Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

    Table 08: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

    Table 09: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

    Table 10: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 11: Europe Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 12: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

    Table 13: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

    Table 14: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

    Table 15: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 16: Asia Pacific Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

    Table 18: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

    Table 19: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

    Table 20: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Latin America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

    Table 23: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

    Table 24: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

    Table 25: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 26: Middle East & Africa Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 27: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031

    Table 28: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031

    Table 29: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031

    Table 30: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    List of Figures

    Figure 01: Global Brucellosis Vaccine Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Brucellosis Vaccine Market Value Share, by Type, 2020

    Figure 03: Global Brucellosis Vaccine Market Value Share, by Vaccine Type, 2020

    Figure 04: Global Brucellosis Vaccine Market Value Share, by Region, 2020

    Figure 05: Global Brucellosis Vaccine Market Value Share, by Application, 2020

    Figure 06: Global Brucellosis Vaccine Market Value Share, by Distribution Channel, 2020

    Figure 07: Global Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

    Figure 08: Global Brucellosis Vaccine Market Revenue (US$ Mn), by RB51 Vaccine, 2017–2031

    Figure 09: Global Brucellosis Vaccine Market Revenue (US$ Mn), by S19 Vaccine, 2017–2031

    Figure 10: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 11: Global Brucellosis Vaccine Market Attractiveness Analysis, by Type, 2021–2031

    Figure 12: Global Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

    Figure 13: Global Brucellosis Vaccine Market Revenue (US$ Mn), by DNA Vaccine, 2017–2031

    Figure 14: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Subunit Vaccine, 2017–2031

    Figure 15: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Vector Vaccine, 2017–2031

    Figure 16: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Recombinant Vaccine, 2017–2031

    Figure 17: Global Brucellosis Vaccine Market Attractiveness Analysis, by Vaccine Type, 2021–2031

    Figure 18: Global Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

    Figure 19: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Cattle, 2017–2031

    Figure 20: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Sheep & Goat, 2017–2031

    Figure 21: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 22: Global Brucellosis Vaccine Market Attractiveness Analysis, by Application, 2021–2031

    Figure 23: Global Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 24: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Veterinary Hospitals & Clinics, 2017–2031

    Figure 25: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Retail Channels, 2017–2031

    Figure 26: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 27: Global Brucellosis Vaccine Market Attractiveness Analysis, by Distribution Channel, 2021–2031

    Figure 28: Global Brucellosis Vaccine Market Value Share Analysis, by Region, 2020 and 2031

    Figure 29: Global Brucellosis Vaccine Market Analysis, by Region, 2021-2031

    Figure 30: North America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 31: North America Brucellosis Vaccine Market Value Share (%), by Country, 2020 and 2031

    Figure 32: North America Brucellosis Vaccine Market Attractiveness, by Country, 2021–2031

    Figure 33: North America Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

    Figure 34: North America Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

    Figure 35: North America Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

    Figure 36: North America Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

    Figure 37: North America Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

    Figure 38: North America Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

    Figure 39: North America Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 40: North America Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

    Figure 41: Europe Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 42: Europe Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 43: Europe Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

    Figure 44: Europe Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

    Figure 45: Europe Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

    Figure 46: Europe Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

    Figure 47: Europe Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

    Figure 48: Europe Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

    Figure 49: Europe Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

    Figure 50: Europe Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 51: Europe Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

    Figure 52: Asia Pacific Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 53: Asia Pacific Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 54: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

    Figure 55: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

    Figure 56: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

    Figure 57: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

    Figure 58: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

    Figure 59: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

    Figure 60: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

    Figure 61: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 62: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

    Figure 63: Latin America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 64: Latin America Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 65: Latin America Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

    Figure 66: Latin America Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

    Figure 67: Latin America Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

    Figure 68: Latin America Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

    Figure 69: Latin America Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

    Figure 70: Latin America Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

    Figure 71: Latin America Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

    Figure 72: Latin America Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 73: Latin America Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

    Figure 74: Middle East & Africa Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 75: Middle East & Africa Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031

    Figure 76: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031

    Figure 77: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031

    Figure 78: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031

    Figure 79: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031

    Figure 80: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031

    Figure 81: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031

    Figure 82: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031

    Figure 83: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031

    Figure 84: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031

Copyright © Transparency Market Research, Inc. All Rights reserved

Brucellosis Vaccine Market Outlook, 2021-2031

Schedule a Call